大连医科大学学报
大連醫科大學學報
대련의과대학학보
JOURNAL OF DALIAN MEDICAL UNIVERSITY
2015年
2期
105-108
,共4页
肠促胰素%糖尿病肾病%GLP-1%GLP-1受体激动剂%DPP-4%DPP-4抑制剂
腸促胰素%糖尿病腎病%GLP-1%GLP-1受體激動劑%DPP-4%DPP-4抑製劑
장촉이소%당뇨병신병%GLP-1%GLP-1수체격동제%DPP-4%DPP-4억제제
Incretin%diabetic nephropathy%GLP-1%GLP-1 receptor agonists%DPP-4%DPP-4 inhibitors
基于肠促胰素的治疗包括胰高血糖素样肽（ GLP－1）受体激动剂和二肽基肽酶4（ DPP－4）抑制剂，这类药物能够改善机体高血糖状态，保护β细胞功能，无体重增加，从而延缓糖尿病肾病病程的进展。此外，这类药物的胰腺外作用及GLP－1的依赖性和非依赖效应在糖尿病肾病中起着独特的作用，并引起广泛关注。本文综述了相关方面的前期临床和临床研究数据，提示这类药物对肾脏存在保护作用以及对血压及尿蛋白有改善作用，可能在糖尿病肾病中有着广泛的应用前景。
基于腸促胰素的治療包括胰高血糖素樣肽（ GLP－1）受體激動劑和二肽基肽酶4（ DPP－4）抑製劑，這類藥物能夠改善機體高血糖狀態，保護β細胞功能，無體重增加，從而延緩糖尿病腎病病程的進展。此外，這類藥物的胰腺外作用及GLP－1的依賴性和非依賴效應在糖尿病腎病中起著獨特的作用，併引起廣汎關註。本文綜述瞭相關方麵的前期臨床和臨床研究數據，提示這類藥物對腎髒存在保護作用以及對血壓及尿蛋白有改善作用，可能在糖尿病腎病中有著廣汎的應用前景。
기우장촉이소적치료포괄이고혈당소양태（ GLP－1）수체격동제화이태기태매4（ DPP－4）억제제，저류약물능구개선궤체고혈당상태，보호β세포공능，무체중증가，종이연완당뇨병신병병정적진전。차외，저류약물적이선외작용급GLP－1적의뢰성화비의뢰효응재당뇨병신병중기착독특적작용，병인기엄범관주。본문종술료상관방면적전기림상화림상연구수거，제시저류약물대신장존재보호작용이급대혈압급뇨단백유개선작용，가능재당뇨병신병중유착엄범적응용전경。
Incretin-based therapies in the treatment of patients with type 2 diabetes include Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors.This class of compounds can improve hy-perglycemia,protect β-cell function without weight gain,which may partly prevent progression of diabetic nephropathy. Moreover,cumulative data suggest that incretin-based treatments interrupt the pathogenesis of diabetic nephropathy by their pleiotropic positive effects on kidney apart from decreasing glucose.This review focuses on these experimental and clinical studies to highlight the renoprotection effects of incretin-based therapies.Ongoing prospective studies are needed to clarify their possible role in the attenuation of diabetic nephropathy.
